$PRTA
PROTHENA CORP PUBLIC LTD CO

2013 Q2 Form 10-Q Financial Statement

#000119312513331182 Filed on August 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $167.0K $740.0K
YoY Change -77.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.210M $2.430M
YoY Change 32.1%
% of Gross Profit
Research & Development $8.147M $8.019M
YoY Change 1.6%
% of Gross Profit
Depreciation & Amortization $200.0K $100.0K
YoY Change 100.0% -75.0%
% of Gross Profit
Operating Expenses $11.36M $10.45M
YoY Change 8.74%
Operating Profit -$11.19M -$9.711M
YoY Change 15.25%
Interest Expense $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $14.00K
YoY Change
Pretax Income -$11.18M -$9.711M
YoY Change 15.11%
Income Tax $124.0K $0.00
% Of Pretax Income
Net Earnings -$11.30M -$9.711M
YoY Change 16.38%
Net Earnings / Revenue -6767.66% -1312.3%
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$0.64 -$669.7K
COMMON SHARES
Basic Shares Outstanding 17.68M shares
Diluted Shares Outstanding 17.68M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.5M
YoY Change
Cash & Equivalents $112.5M
Short-Term Investments
Other Short-Term Assets $1.100M $100.0K
YoY Change 1000.0%
Inventory
Prepaid Expenses
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $113.6M $100.0K
YoY Change 113494.0%
LONG-TERM ASSETS
Property, Plant & Equipment $3.729M $2.500M
YoY Change 49.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $900.0K
YoY Change -33.33%
Total Long-Term Assets $4.336M $3.500M
YoY Change 23.89%
TOTAL ASSETS
Total Short-Term Assets $113.6M $100.0K
Total Long-Term Assets $4.336M $3.500M
Total Assets $117.9M $3.600M
YoY Change 3175.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $779.0K $300.0K
YoY Change 159.67%
Accrued Expenses $6.900M $4.000M
YoY Change 72.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.083M $4.400M
YoY Change 106.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.400M $1.800M
YoY Change -22.22%
Total Long-Term Liabilities $1.400M $1.800M
YoY Change -22.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.083M $4.400M
Total Long-Term Liabilities $1.400M $1.800M
Total Liabilities $10.70M $6.200M
YoY Change 72.6%
SHAREHOLDERS EQUITY
Retained Earnings -$20.60M
YoY Change
Common Stock $177.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.2M -$2.600M
YoY Change
Total Liabilities & Shareholders Equity $117.9M $3.600M
YoY Change 3175.83%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$11.30M -$9.711M
YoY Change 16.38%
Depreciation, Depletion And Amortization $200.0K $100.0K
YoY Change 100.0% -75.0%
Cash From Operating Activities -$6.860M -$10.37M
YoY Change -33.85% 12.72%
INVESTING ACTIVITIES
Capital Expenditures -$230.0K -$30.00K
YoY Change 666.67% -90.0%
Acquisitions
YoY Change
Other Investing Activities $30.00K $0.00
YoY Change
Cash From Investing Activities -$200.0K -$30.00K
YoY Change 566.67% -90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 10.40M
YoY Change -100.0% 9.47%
NET CHANGE
Cash From Operating Activities -6.860M -10.37M
Cash From Investing Activities -200.0K -30.00K
Cash From Financing Activities 0.000 10.40M
Net Change In Cash -7.060M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$6.860M -$10.37M
Capital Expenditures -$230.0K -$30.00K
Free Cash Flow -$6.630M -$10.34M
YoY Change -35.88% 16.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
0.18 pure
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17679182 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17679182000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17679182000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
530000
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3909000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127650000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
779000
CY2013Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9083000
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1185000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
107229000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20598000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1417000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
177000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117930000
CY2013Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
201000
CY2013Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
300000
CY2013Q2 us-gaap Liabilities
Liabilities
10701000
CY2013Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2306000
CY2013Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
55000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
113594000
CY2013Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1920000
CY2013Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
607000
CY2013Q2 us-gaap Assets
Assets
117930000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112507000
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7638000
CY2013Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
4336000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
959000
CY2013Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
85000
CY2013Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
73000
CY2013Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5633000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3729000
CY2013Q2 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5698000
CY2013Q2 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2013Q2 prta Deferred Shares Value
DeferredSharesValue
CY2013Q2 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
shares
CY2013Q2 prta Deferred Shares Share Issued
DeferredSharesShareIssued
shares
CY2013Q2 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17679182000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17679182000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
51000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3743000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126652000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1744000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1592000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
126484000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1055000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
177000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129283000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
27000
CY2012Q4 us-gaap Liabilities
Liabilities
2799000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1670000
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
223000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
125841000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1651000
CY2012Q4 us-gaap Assets
Assets
129283000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124860000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7185000
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3442000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
685000
CY2012Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
85000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
73000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5449000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3442000
CY2012Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
47000
CY2012Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2012Q4 prta Deferred Shares Value
DeferredSharesValue
CY2012Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
shares
CY2012Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
shares
CY2012Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000000 shares
dei Trading Symbol
TradingSymbol
PRTA
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Registrant Name
EntityRegistrantName
Prothena Corp plc
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001559053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Description of Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Prothena Corporation plc (&#x201C;Prothena,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;our&#x201D; or &#x201C;us&#x201D;), a public limited company incorporated in Ireland, is a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion. The Company is focused on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. These potential therapies have a broad range of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson&#x2019;s disease and related synucleinopathies (PRX002) and autoimmune diseases and metastatic cancers (PRX003). The Company has initiated a Phase 1 clinical trial for NEOD001 with the first patient dosing in April 2013. The Phase 1 clinical trial of NEOD001 will evaluate safety and tolerability in AL Amyloidosis patients. The Company&#x2019;s strategy is to identify antibody candidates for clinical development by applying its extensive expertise in generating novel therapeutic antibodies and working with collaborators having expertise in specific animal models of disease.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Prothena&#x2019;s business consists of a substantial portion of Elan Corporation plc&#x2019;s (&#x201C;Elan&#x201D;) former drug discovery business platform, including Neotope Biosciences Limited (and its wholly-owned subsidiary Prothena Biosciences Inc) and Onclave Therapeutics Limited, each former wholly-owned subsidiaries of Elan (which for the period prior to separation and distribution are referred to herein as the &#x201C;Prothena Business&#x201D;). Effective December&#xA0;20, 2012, the Prothena Business separated from Elan.</font></p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17679000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11958000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
prta Post Separation Adjustments To Funding Provided By Related Party
PostSeparationAdjustmentsToFundingProvidedByRelatedParty
84000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1836000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the condensed consolidated financial statements in conformity with Generally Accepted Accounting Principles in the United States (&#x201C;GAAP&#x201D;) requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></p> </div>
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-168000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
338000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
29000
us-gaap Income Taxes Paid
IncomeTaxesPaid
263000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
36000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
274000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20159000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
340000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20123000
us-gaap Net Income Loss
NetIncomeLoss
-20253000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7470000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6393000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-84000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-406000
us-gaap Share Based Compensation
ShareBasedCompensation
1082000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12353000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
29000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-311000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14104000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
284000
us-gaap Depreciation
Depreciation
300000
us-gaap Operating Expenses
OperatingExpenses
20497000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
130000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14497000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18988000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.42
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1424000 shares
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1139000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20522000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
171000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20522000
us-gaap Net Income Loss
NetIncomeLoss
-20522000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3913000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4885000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19159000
us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
19159000
us-gaap Share Based Compensation
ShareBasedCompensation
5225000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16776000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
228000
us-gaap Depreciation
Depreciation
200000
us-gaap Operating Expenses
OperatingExpenses
21661000
prta Centralized Support Cost
CentralizedSupportCost
4100000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14497000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2012Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
735000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9711000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9711000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-9711000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2427000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8019000
CY2012Q2 us-gaap Depreciation
Depreciation
100000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
10446000
CY2012Q2 prta Centralized Support Cost
CentralizedSupportCost
2100000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17679000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
167000
CY2013Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
14000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11192000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11178000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-11302000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3212000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8147000
CY2013Q2 us-gaap Depreciation
Depreciation
200000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
11359000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
124000

Files In Submission

Name View Source Status
0001193125-13-331182-index-headers.html Edgar Link pending
0001193125-13-331182-index.html Edgar Link pending
0001193125-13-331182.txt Edgar Link pending
0001193125-13-331182-xbrl.zip Edgar Link pending
d539909d10q.htm Edgar Link pending
d539909dex102.htm Edgar Link pending
d539909dex103.htm Edgar Link pending
d539909dex311.htm Edgar Link pending
d539909dex312.htm Edgar Link pending
d539909dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g539909g37z65.jpg Edgar Link pending
g539909img1.jpg Edgar Link pending
prta-20130630.xml Edgar Link completed
prta-20130630.xsd Edgar Link pending
prta-20130630_cal.xml Edgar Link unprocessable
prta-20130630_def.xml Edgar Link unprocessable
prta-20130630_lab.xml Edgar Link unprocessable
prta-20130630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending